RBC Capital Lifts CRISPR Therapeutics (CRSP) Target to $50, Keeps Sector Perform

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, RBC Capital raised its price target for CRISPR Therapeutics AG (NASDAQ:CRSP) stock from $42 to $50. The firm kept the Sector Perform rating on the shares.

The analysts noted that CASGEVY, CRISPR’s leading product, missed its sales expectations in Q3 2025 – revenue from the product was $17 million, compared to a consensus estimate of $41 million. Also, the number of CASGEVY infusions fell from 16 in Q2 to 10 in Q3.​ But despite this underperformance, RBC Capital noted that Vertex Pharmaceuticals (CRISPR’s partner) projects over $100 million in total CASGEVY revenue for 2025. The analysts see this as an indication of more than $39 million in expected Q4 sales.

Separately, on the same day, Citizens affirmed its Market Outperform and an $86 price target on CRISPR stock, citing promising Phase 1 data for its CTX310 treatment. This treatment targets and destroys blood fats, specifically ANGPTL3, which contributes to the development of heart disease in individuals with cholesterol disorders. The analysts pointed out that Phase 1 data showed significant reductions in circulating ANGPTL3, supporting the in-vivo program’s promise.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a biopharmaceutical company. It develops transformative gene-based medicines using its proprietary CRISPR/Cas9 gene-editing technology. Its main products include CASGEVY, the first FDA-approved CRISPR-based therapy for sickle cell disease and transfusion-dependent beta-thalassemia, as well as a pipeline of candidates, such as CTX310 for lipid disorders and CTX112 for oncology and autoimmune diseases.

While we acknowledge the potential of CRSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best European Bank Stocks to Buy Now and 11 Best Solar Energy Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.